Antidepressant-like effect of the organoselenium compound ebselen in mice: Evidence for the involvement of the monoaminergic system

European Journal of Pharmacology

Volumn 602, Issue 1, 2009, Pages 85-91

  Posser, Thaís ^a   Kaster, Manuella P ^a   Baraúna, Sara Cristiane ^a   Rocha, João B T ^b   Rodrigues, Ana Lúcia S ^a   Leal, Rodrigo B ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Antidepressant like effect; Dopaminergic system; Ebselen; Forced swimming test; Noradrenergic system

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; EBSELEN; FENCLONINE; KETANSERIN; PRAZOSIN; SULPIRIDE; YOHIMBINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG MECHANISM; FORCED SWIMMING TEST; MALE; MONOAMINERGIC SYSTEM; MOUSE; NONHUMAN; NORADRENERGIC SYSTEM; OPEN FIELD TEST; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM;

EID: 84984589123     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.10.055     Document Type: Article

References (76)

1. Ansorge M.S., Hen R., and Gingrich J.A. Neurodevelopmental origins of depressive disorders. Curr. Opin. Pharmacol. 7 (2007) 8-17
2. Barauna S.C., Kaster M.P., Heckert B.T., do Nascimento K.S., Rossi F.M., Teixeira E.H., Cavada B.S., Rodrigues A.L.S., and Leal R.B. Antidepressant-like effect of lectin from Canavalia brasiliensis (ConBr) administered centrally in mice. Pharmacol. Biochem. Behav. 85 (2006) 160-169
3. Berton O., and Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev., Neurosci. 7 (2006) 137-151
4. Bilici M., Efe H., Koroglu M.A., Uydu H.A., Bekaroglu M., and Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J. Affect. Disord. 64 (2001) 43-51
5. Brocardo P.S., Assini F., Franco J.L., Pandolfo P., Muller Y.M., Takahashi R.N., Dafre A.L., and Rodrigues A.L.S. Zinc attenuates malathion-induced depressant-like behavior and confers neuroprotection in the rat brain. Toxicol. Sci. 97 (2007) 140-148
6. Burger M.E., Fachinetto R., Zeni G., and Rocha J.B. Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain. Pharmacol. Biochem. Behav. 81 (2005) 608-615
7. Bymaster F.P., Zhang W., Carter P.A., Shaw J., Chernet E., Phebus L., Wong D.T., and Perry K.W. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 160 (2002) 353-361
8. Chen B.T., Avshalumov M.V., and Rice M.E. H(2)O(2) is a novel, endogenous modulator of synaptic dopamine release. J. Neurophysiol. 85 (2001) 2468-2476
9. Chiodo L.A., and Antelman S.M. Repeated tricyclics induce a progressive dopamine autoreceptor subsensitivity independent of daily drug treatment. Nature 287 (1980) 451-454
10. Cryan J.F., Markou A., and Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 23 (2002) 238-245
11. Cryan J.F., O'Leary O.F., Jin S.H., Friedland J.C., Ouyang M., Hirsch B.R., Page M.E., Dalvi A., Thomas S.A., and Lucki I. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc.Natl. Acad. Sci. U S A 101 (2004) 8186-8191
12. Cryan J.F., Mombereau C., and Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. 29 (2005) 571-625
13. Dailly E., Chenu F., Renard C.E., and Bourin M. Dopamine, depression and antidepressants. Fundam. Clin. Pharmacol. 18 (2004) 601-607
14. Danysz W., Kostowski W., Kozak W., and Hauptmann M. On the role of noradrenergic neurotransmission in the action of desipramine and amitriptyline in animal models of depression. Pol. J. Pharmacol. Pharm. 38 (1986) 285-298
15. D'Aquila P.S., Collu M., Gessa G.L., and Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur. J. Pharmacol. 405 (2000) 365-373
16. Dimmeler S., Brune B., and Ullrich V. Ebselen prevents inositol (1,4,5)-trisphosphate binding to its receptor. Biochem. Pharmacol. 42 (1991) 1151-1153
17. Dziedzicka-Wasylewska M., Kolasiewicz W., Rogoz Z., Margas W., and Maj J. The role of dopamine D2 receptor in the behavioral effects of imipramine-study with the use of antisense oligonucleotides. J. Physiol. Pharmacol. 51 (2000) 401-409
18. Elhwuegi A.S. Central monoamines and their role in major depression. Prog Neuro-psychopharmacol. Biol. Psychiatry 28 (2004) 435-451
19. Engman L. Expedient synthesis of ebselen and related compounds. J. Org. Chem. 54 (1989) 2964-2966
20. Eren I., Naziroglu M., and Demirdas A. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem. Res. 32 (2007) 1188-1195
21. Farina M., Frizzo M.E., Soares F.A., Schwalm F.D., Dietrich M.O., Zeni G., Rocha J.B., and Souza D.O. Ebselen protects against methylmercury-induced inhibition of glutamate uptake by cortical slices from adult mice. Toxicol. Lett. 144 (2003) 351-357
22. Gilman S.C., Bonner M.J., and Pellmar T.C. Peroxide effects on [3H]L-glutamate release by synaptosomes isolated from the cerebral cortex. Neurosci. Lett. 140 (1992) 157-160
23. Herin G.A., Du S., and Aizenman E. The neuroprotective agent ebselen modifies NMDA receptor function via the redox modulatory site. J. Neurochem. 78 (2001) 1307-1314
24. Herken H., Gurel A., Selek S., Armutcu F., Ozen M.E., Bulut M., Kap O., Yumru M., Savas H.A., and Akyol O. Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment. Arch. Med. Res. 38 (2007) 247-252
25. Huang Y.Y., Peng C.H., Yang Y.P., Wu C.C., Hsu W.M., Wang H.J., Chan K.H., Chou Y.P., Chen S.J., and Chang Y.L. Desipramine activated Bcl-2 expression and inhibited lipopolysaccharide-induced apoptosis in hippocampus-derived adult neural stem cells. J. Pharmacol. Sci. 104 (2007) 61-72
26. Imai H., Graham D.I., Masayasu H., and Macrae I.M. Antioxidant ebselen reduces oxidative damage in focal cerebral ischemia. Free Radic. Biol. Med. 34 (2003) 56-63
27. Jacob C., Maret W., and Vallee B.L. Control of zinc transfer between thionein, metallothionein, and zinc proteins. Proc. Natl. Acad. Sci. U S A 95 (1998) 3489-3494
28. Joseph J.A., Villalobos-Molina R., Denisova N., Erat S., Cutler R., and Strain J. Age differences in sensitivity to H2O2- or NO-induced reductions in K(+)-evoked dopamine release from superfused striatal slices: reversals by PBN or Trolox. Free Radic. Biol. Med. 20 (1996) 821-830
29. Kalayci M., Coskun O., Cagavi F., Kanter M., Armutcu F., Gul S., and Acikgoz B. Neuroprotective effects of ebselen on experimental spinal cord injury in rats. Neurochem. Res. 30 (2005) 403-410
30. 1A receptors in the antidepressant-like effect of adenosine in the mouse forced swimming test. Brain Res. Bull. 67 (2005) 53-61
31. Kaster M.P., Raupp I., Binfare R.W., Andreatini R., and Rodrigues A.L.S. Antidepressant-like effect of lamotrigine in the mouse forced swimming test: evidence for the involvement of the noradrenergic system. Eur. J. Pharmacol. 565 (2007) 119-124
32. Kitada Y., Miyauchi T., Kanazawa Y., Nakamichi H., and Satoh S. Involvement of alpha- and beta 1-adrenergic mechanisms in the immobility-reducing action of desipramine in the forced swimming test. Neuropharmacology 22 (1983) 1055-1060
33. Kolla N., Wei Z., Richardson J.S., and Li X.M. Amitriptyline and fluoxetine protect PC12 cells from cell death induced by hydrogen peroxide. J. Psychiatry Neurosci. 30 (2005) 196-201
34. Machado D.G., Kaster M.P., Binfare R.W., Dias M., Santos A.R.S., Pizzolatti M.G., Brighente I.M., and Rodrigues A.L.S. Antidepressant-like effect of the extract from leaves of Schinus molle L. in mice: evidence for the involvement of the monoaminergic system. Prog. Neuro-psychopharmacol. Biol. Psychiatry 31 (2007) 421-428
35. Michel T.M., Frangou S., Thiemeyer D., Camara S., Jecel J., Nara K., Brunklaus A., Zoechling R., and Riederer P. Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder-a postmortem study. Psychiatry Res. 151 (2007) 145-150
36. Middlemiss D.N., Price G.W., and Watson J.M. Serotonergic targets in depression. Curr. Opin. Pharmacol. 2 (2002) 18-22
37. Millan M.J. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur. J. Pharmacol. 500 (2004) 371-384
38. Mitani H., Shirayama Y., Yamada T., and Kawahara R. Plasma levels of homovanillic acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin turnover in depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 531-534
39. Moretto M.B., Franco J., Posser T., Nogueira C.W., Zeni G., and Rocha J.B. Ebselen protects Ca2+ influx blockage but does not protect glutamate uptake inhibition caused by Hg2+. Neurochem. Res. 29 (2004) 1801-1806
40. Moretto M.B., Funchal C., Santos A.Q., Gottfried C., Boff B., Zeni G., Pureur R.P., Souza D.O., Wofchuk S., and Rocha J.B. Ebselen protects glutamate uptake inhibition caused by methyl mercury but does not by Hg2+. Toxicology 214 (2005) 57-66
41. Muller A., Cadenas E., Graf P., and Sies H. A novel biologically active seleno-organic compound-I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen). Biochem. Pharmacol. 33 (1984) 3235-3239
42. Nestler E.J., Barrot M., DiLeone R.J., Eisch A.J., Gold S.J., and Monteggia L.M. Neurobiology of depression. Neuron 34 (2002) 13-25
43. Nogueira C.W., Zeni G., and Rocha J.B.T. Organoselenium and organotellurium compounds: toxicology and pharmacology. Chem. Rev. 104 (2004) 6255-6285
44. O'Leary O.F., Bechtholt A.J., Crowley J.J., Hill T.E., Page M.E., and Lucki I. Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology (Berl) 192 (2007) 357-371
45. O'Neill M.F., and Conway M.W. Role of 5-HT(1A) and 5-HT(1B) receptors in the mediation of behavior in the forced swim test in mice. Neuropsychopharmacology 24 (2001) 391-398
46. Ozaki M., Nakamura M., Teraoka S., and Ota K. Ebselen, a novel anti-oxidant compound, protects the rat liver from ischemia-reperfusion injury. Transpl. Int. 10 (1997) 96-102
47. Page M.E., Detke M.J., Dalvi A., Kirby L.G., and Lucki I. Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 147 (1999) 162-167
48. Pandey G.N., Sharma R.P., Janicak P.G., and Davis J.M. Monoamine oxidase and cortisol response in depression and schizophrenia. Psychiatry Res. 44 (1992) 1-8
49. Papakostas G.I. Dopaminergic-based pharmacotherapies for depression. Eur Neuropsychopharmacol. 16 (2006) 391-402
50. Peng, C.H., Chiou, S.H., Chen, S.J., Chou, Y.C., Ku, H.H., Cheng, C.K., Yen, C.J., Tsai, T.H., Chang, Y.L., Kao, C.L., 2008. Neuroprotection by Imipramine against lipopolysaccharide-induced apoptosis in hippocampus-derived neural stem cells mediated by activation of BDNF and the MAPK pathway. Eur. Neuropsychopharmacol. 18, 128-140.
51. Petit-Demouliere B., Chenu F., and Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl) 177 (2005) 245-255
52. Porciuncula L.O., Rocha J.B.T., Boeck C.R., Vendite D., and Souza D.O. Ebselen prevents excitotoxicity provoked by glutamate in rat cerebellar granule neurons. Neurosci. Lett. 299 (2001) 217-220
53. Porsolt R., and Lenegre A. Behavioral models of depression. In: Elliott J., Heal D., and Marsden C. (Eds). Experimental Approaches to Anxiety and Depression (1992), Wiley, London 73-85
54. Porsolt R.D., Bertin A., and Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 229 (1977) 327-336
55. Redrobe J.P., and Bourin M. Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test. Eur. J. Pharmacol. 325 (1997) 129-135
56. Redrobe J.P., Bourin M., Colombel M.C., and Baker G.B. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology (Berl) 138 (1998) 1-8
57. Renard C.E., Fiocco A.J., Clenet F., Hascoet M., and Bourin M. Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test?. Psychopharmacology (Berl) 159 (2001) 42-50
58. Richelson R. Pharmacology of antidepressants. Mayo Clin. Proc. 76 (2001) 511-527
59. Rodrigues A.L.S., Rocha J.B.T., Mello C.F., and Souza D.O. Effect of perinatal lead exposure on rat behaviour in open-field and two-way avoidance tasks. Pharmacol. Toxicol. 79 (1996) 150-156
60. Rodrigues A.L.S., da Silva G.L., Mateussi A.S., Fernandes E.S., Miguel O.G., Yunes R.A., Calixto J.B., and Santos A.R.S. Involvement of monoaminergic system in the antidepressant-like effect of the hydroalcoholic extract of Siphocampylus verticillatus. Life Sci. 70 (2002) 1347-1358
61. Saito I., Asano T., Sano K., Takakura K., Abe H., Yoshimoto T., Kikuchi H., Ohta T., and Ishibashi S. Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage. Neurosurgery 42 (1998) 269-277
62. Sarandol A., Sarandol E., Eker S.S., Karaagac E.U., Hizli B.Z., Dirican M., and Kirli S. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Prog Neuro-psychopharmacol. Biol. Psychiatry 30 (2006) 1103-1108
63. Savegnago L., Jesse C.R., Pinto L.G., Rocha J.B.T., Nogueira C.W., and Zeni G. Monoaminergic agents modulate antidepressant-like effect caused by diphenyl diselenide in rats. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 31 (2007) 1261-1269
64. Schewe T. Molecular actions of ebselen-an antiinflammatory antioxidant. Gen. Pharmacol. 26 (1995) 1153-1169
65. Serra G., Collu M., D'Aquila P.S., De Montis G.M., and Gessa G.L. Possible role of dopamine D1 receptor in the behavioural supersensitivity to dopamine agonists induced by chronic treatment with antidepressants. Brain Res. 527 (1990) 234-243
66. Sher L., Mann J.J., Traskman-Bendz L., Winchel R., Huang Y.Y., Fertuck E., and Stanley B.H. Lower cerebrospinal fluid homovanillic acid levels in depressed suicide attempters. J. Affect. Disord. 90 (2006) 83-89
67. Sies H. Ebselen, a selenoorganic compound as glutathione peroxidase mimic. Free Radic. Biol. Med. 14 (1993) 313-323
68. Steru L., Chermat R., Thierry B., and Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85 (1985) 367-370
69. Takuma K., Baba A., and Matsuda T. Astrocyte apoptosis: implications for neuroprotection. Prog. Neurobiol. 72 (2004) 111-127
70. Tsai S. Glatiramer acetate could be a potential antidepressant through its neuroprotective and anti-inflammatory effects. Med. Hypotheses 69 (2007) 145-148
71. Urani A., Chourbaji S., and Gass P. Mutant mouse models of depression: candidate genes and current mouse lines. Neurosci. Biobehav. Rev. 29 (2005) 805-828
72. Wong M.L., and Licinio J. Research and treatment approaches to depression. Nat. Rev. Neurosci. 2 (2001) 343-351
73. Xu J.H., Hu H.T., Liu Y., Qian Y.H., Liu Z.H., Tan Q.R., and Zhang Z.J. Neuroprotective effects of ebselen are associated with the regulation of Bcl-2 and Bax proteins in cultured mouse cortical neurons. Neurosci. Lett. 399 (2006) 210-214
74. Yamada J., Sugimoto Y., and Yamada S. Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test. Eur. J. Pharmacol. 504 (2004) 207-211
75. Yamaguchi T., Sano K., Takakura K., Saito I., Shinohara Y., Asano T., and Yasuhara H. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke 29 (1998) 12-17
76. Zoccarato F., Valente M., and Alexandre A. Hydrogen peroxide induces a long-lasting inhibition of the Ca(2+)-dependent glutamate release in cerebrocortical synaptosomes without interfering with cytosolic Ca2+. J. Neurochem. 64 (1995) 2552-2558